U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula 2C17H23NO3.H2O.H2O4S
Molecular Weight 694.833
Optical Activity ( + / - )
Defined Stereocenters 6 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ATROPINE SULFATE

SMILES

O.OS(O)(=O)=O.CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C3=CC=CC=C3.CN4[C@H]5CC[C@@H]4C[C@@H](C5)OC(=O)C(CO)C6=CC=CC=C6

InChI

InChIKey=JPKKQJKQTPNWTR-CHYDPLAESA-N
InChI=1S/2C17H23NO3.H2O4S.H2O/c2*1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12;1-5(2,3)4;/h2*2-6,13-16,19H,7-11H2,1H3;(H2,1,2,3,4);1H2/t2*13-,14+,15+,16?;;

HIDE SMILES / InChI

Molecular Formula C17H23NO3
Molecular Weight 289.3694
Charge 0
Count
Stereochemistry EPIMERIC
Additional Stereochemistry No
Defined Stereocenters 3 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula H2O4S
Molecular Weight 98.078
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68001285 | http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206289s000lbl.pdf

Atropine inhibits the muscarinic actions of acetylcholine on structures innervated by postganglionic cholinergic nerves, and on smooth muscles which respond to endogenous acetylcholine but are not so innervated. As with other antimuscarinic agents, the major action of atropine is a competitive or surmountable antagonism which can be overcome by increasing the concentration of acetylcholine at receptor sites of the effector organ (e.g., by using anticholinesterase agents which inhibit the enzymatic destruction of acetylcholine). The receptors antagonized by atropine are the peripheral structures that are stimulated or inhibited by muscarine (i.e., exocrine glands and smooth and cardiac muscle). Responses to postganglionic cholinergic nerve stimulation also may be inhibited by atropine but this occurs less readily than with responses to injected (exogenous) choline esters. Atropine is relatively selective for muscarinic receptors. Its potency at nicotinic receptors is much lower, and actions at non-muscarinic receptors are generally undetectable clinically. Atropine does not distinguish among the M1, M2, and M3 subgroups of muscarinic receptors.

Originator

Curator's Comment: Atropine was first obtained from the deadly nightshade (Atropa belladonna) by M. Brandes in 1819.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Atropine sulfate

Approved Use

Atropine sulfate is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest.

Launch Date

2001
Primary
Atropine sulfate

Approved Use

Atropine sulfate is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest.

Launch Date

2001
Primary
Atropine sulfate

Approved Use

Atropine sulfate is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest.

Launch Date

2001
Primary
Atropine sulfate

Approved Use

Atropine sulfate is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest.

Launch Date

2001
Primary
Atropine sulfate

Approved Use

Atropine sulfate is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest.

Launch Date

2001
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
860 pg/mL
0.4 μg single, ocular
dose: 0.4 μg
route of administration: Ocular
experiment type: SINGLE
co-administered:
ATROPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
11.7 ng/mL
1.67 mg single, intramuscular
dose: 1.67 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
ATROPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
9.6 ng/mL
1.67 mg single, intramuscular
dose: 1.67 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
ATROPINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
43245 pg × min/mL
0.4 μg single, ocular
dose: 0.4 μg
route of administration: Ocular
experiment type: SINGLE
co-administered:
ATROPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
47.6 ng × h/mL
1.67 mg single, intramuscular
dose: 1.67 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
ATROPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.1 h
1.67 mg single, intramuscular
dose: 1.67 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
ATROPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
82%
1.67 mg single, intramuscular
dose: 1.67 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
ATROPINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.1 mg/kg single, intravenous
Dose: 0.1 mg/kg
Route: intravenous
Route: single
Dose: 0.1 mg/kg
Sources:
unhealthy, 10 years
n = 1
Health Status: unhealthy
Age Group: 10 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Kounis syndrome, Chest discomfort...
AEs leading to
discontinuation/dose reduction:
Kounis syndrome (1 patient)
Chest discomfort (1 patient)
Nausea (1 patient)
Vomiting (1 patient)
Sources:
0.5 % 1 times / day multiple, ophthalmic
Highest studied dose
Dose: 0.5 %, 1 times / day
Route: ophthalmic
Route: multiple
Dose: 0.5 %, 1 times / day
Sources:
unhealthy, 10.3 years (range: 2.7–16.8 years)
n = 77
Health Status: unhealthy
Condition: progressive myopia
Age Group: 10.3 years (range: 2.7–16.8 years)
Sex: M+F
Population Size: 77
Sources:
Other AEs: Photophobia, Reading disorder...
Other AEs:
Photophobia (70%)
Reading disorder (25.9%)
Headache (21.7%)
Hot flushes (3.3%)
Conjunctivitis (1.7%)
Blepharitis (1.7%)
Sources:
1 mg single, sublingual
Overdose
Dose: 1 mg
Route: sublingual
Route: single
Dose: 1 mg
Sources:
unhealthy
n = 1
Health Status: unhealthy
Population Size: 1
Sources:
Other AEs: Adverse event...
Other AEs:
Adverse event (severe)
Sources:
AEs

AEs

AESignificanceDosePopulation
Chest discomfort 1 patient
Disc. AE
0.1 mg/kg single, intravenous
Dose: 0.1 mg/kg
Route: intravenous
Route: single
Dose: 0.1 mg/kg
Sources:
unhealthy, 10 years
n = 1
Health Status: unhealthy
Age Group: 10 years
Sex: M
Population Size: 1
Sources:
Kounis syndrome 1 patient
Disc. AE
0.1 mg/kg single, intravenous
Dose: 0.1 mg/kg
Route: intravenous
Route: single
Dose: 0.1 mg/kg
Sources:
unhealthy, 10 years
n = 1
Health Status: unhealthy
Age Group: 10 years
Sex: M
Population Size: 1
Sources:
Nausea 1 patient
Disc. AE
0.1 mg/kg single, intravenous
Dose: 0.1 mg/kg
Route: intravenous
Route: single
Dose: 0.1 mg/kg
Sources:
unhealthy, 10 years
n = 1
Health Status: unhealthy
Age Group: 10 years
Sex: M
Population Size: 1
Sources:
Vomiting 1 patient
Disc. AE
0.1 mg/kg single, intravenous
Dose: 0.1 mg/kg
Route: intravenous
Route: single
Dose: 0.1 mg/kg
Sources:
unhealthy, 10 years
n = 1
Health Status: unhealthy
Age Group: 10 years
Sex: M
Population Size: 1
Sources:
Blepharitis 1.7%
0.5 % 1 times / day multiple, ophthalmic
Highest studied dose
Dose: 0.5 %, 1 times / day
Route: ophthalmic
Route: multiple
Dose: 0.5 %, 1 times / day
Sources:
unhealthy, 10.3 years (range: 2.7–16.8 years)
n = 77
Health Status: unhealthy
Condition: progressive myopia
Age Group: 10.3 years (range: 2.7–16.8 years)
Sex: M+F
Population Size: 77
Sources:
Conjunctivitis 1.7%
0.5 % 1 times / day multiple, ophthalmic
Highest studied dose
Dose: 0.5 %, 1 times / day
Route: ophthalmic
Route: multiple
Dose: 0.5 %, 1 times / day
Sources:
unhealthy, 10.3 years (range: 2.7–16.8 years)
n = 77
Health Status: unhealthy
Condition: progressive myopia
Age Group: 10.3 years (range: 2.7–16.8 years)
Sex: M+F
Population Size: 77
Sources:
Headache 21.7%
0.5 % 1 times / day multiple, ophthalmic
Highest studied dose
Dose: 0.5 %, 1 times / day
Route: ophthalmic
Route: multiple
Dose: 0.5 %, 1 times / day
Sources:
unhealthy, 10.3 years (range: 2.7–16.8 years)
n = 77
Health Status: unhealthy
Condition: progressive myopia
Age Group: 10.3 years (range: 2.7–16.8 years)
Sex: M+F
Population Size: 77
Sources:
Reading disorder 25.9%
0.5 % 1 times / day multiple, ophthalmic
Highest studied dose
Dose: 0.5 %, 1 times / day
Route: ophthalmic
Route: multiple
Dose: 0.5 %, 1 times / day
Sources:
unhealthy, 10.3 years (range: 2.7–16.8 years)
n = 77
Health Status: unhealthy
Condition: progressive myopia
Age Group: 10.3 years (range: 2.7–16.8 years)
Sex: M+F
Population Size: 77
Sources:
Hot flushes 3.3%
0.5 % 1 times / day multiple, ophthalmic
Highest studied dose
Dose: 0.5 %, 1 times / day
Route: ophthalmic
Route: multiple
Dose: 0.5 %, 1 times / day
Sources:
unhealthy, 10.3 years (range: 2.7–16.8 years)
n = 77
Health Status: unhealthy
Condition: progressive myopia
Age Group: 10.3 years (range: 2.7–16.8 years)
Sex: M+F
Population Size: 77
Sources:
Photophobia 70%
0.5 % 1 times / day multiple, ophthalmic
Highest studied dose
Dose: 0.5 %, 1 times / day
Route: ophthalmic
Route: multiple
Dose: 0.5 %, 1 times / day
Sources:
unhealthy, 10.3 years (range: 2.7–16.8 years)
n = 77
Health Status: unhealthy
Condition: progressive myopia
Age Group: 10.3 years (range: 2.7–16.8 years)
Sex: M+F
Population Size: 77
Sources:
Adverse event severe
1 mg single, sublingual
Overdose
Dose: 1 mg
Route: sublingual
Route: single
Dose: 1 mg
Sources:
unhealthy
n = 1
Health Status: unhealthy
Population Size: 1
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [IC50 1.2 uM]
yes [IC50 39 uM]
yes [IC50 466 uM]
PubMed

PubMed

TitleDatePubMed
TIVA with propofol and remifentanil.
1999 May
Profound bradycardia and hypotension following spinal anaesthesia in a patient receiving an ACE inhibitor: an important 'drug' interaction?
1999 Nov
Effects of topical glucocorticoids on in vitro lactoferrin glandular secretion: comparison between human upper and lower airways.
2000 Dec
Focal microinjection of carbachol into the periaqueductal gray induces seizures in the forebrain of the rat.
2000 Dec
Effect of alpha-2 adrenoceptor antagonists on colonic function in rats.
2000 Jun
Near fatal case of atrio-ventricular block induced by amitriptyline at therapeutic dose.
2000 Sep
SCH 23390 affords protection against soman-evoked seizures in the freely moving guinea-pig: a concomitant neurochemical, electrophysiological and behavioural study.
2001
Influence of nitric oxide donors and of the alpha(2)-agonist UK-14,304 on acetylcholine release in the pig gastric fundus.
2001
Differences in electromechanical coupling between bradykinin and the nonpeptide kinin B2 receptor agonist, FR 190997, in the circular muscle of guinea-pig colon.
2001 Feb
On the mechanisms of cholinergic control of the sinoatrial node discharge.
2001 Feb
Antispasmodic activity of the fruits of Helicteres isora Linn.
2001 Feb
Sublingual hyoscyamine sulfate in combination with ketorolac tromethamine for ureteral colic: a randomized, double-blind, controlled trial.
2001 Feb
Reversal of rocuronium with edrophonium during propofol versus sevoflurane anesthesia.
2001 Feb
Muscarinic receptor subtypes and calcium signaling in Fischer rat thyroid cells.
2001 Feb 1
Acetylcholine-evoked calcium increases in Deiters' cells of the guinea pig cochlea suggest alpha9-like receptors.
2001 Feb 1
Mechanisms of hydrogen peroxide-induced relaxation in rabbit mesenteric small artery.
2001 Feb 2
Stimulation of M3 muscarinic receptors induces phosphorylation of the Cdc42 effector activated Cdc42Hs-associated kinase-1 via a Fyn tyrosine kinase signaling pathway.
2001 Feb 23
Preanaesthetic use of atropine in small animals.
2001 Jan
[Marked bradycardia during anesthetic induction treated with temporary cardiac pacing in a patient with latent sick sinus syndrome].
2001 Jan
Tachykinins contribute to nerve-mediated contractions in the human esophagus.
2001 Jan
Tris(2,2'-bipyridine)ruthenium(II) electrogenerated chemiluminescence of alkaloid type drugs with solid phase extraction sample preparation.
2001 Jan
Muscarinic activation of transient inward current and contraction in canine colon circular smooth muscle cells.
2001 Jan
Spectral analysis of circadian rhythms in heart rate variability of dogs.
2001 Jan
Effects of VIP and NO on the motor activity of vascularly perfused rat proximal colon.
2001 Jan
Unplanned administration of atropine, succinylcholine and lidocaine.
2001 Jan
Neuropharmacological actions of some binuclear lanthanide(III) complexes.
2001 Jan
Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecan.
2001 Jan
Comparison of myocardial blood flow during dobutamine-atropine infusion with that after dipyridamole administration in normal men.
2001 Jan
Reversal of Haemorrhagic Shock in Rats by Tetrahydroaminoacridine.
2001 Jan
Administration of atropine in the setting of acute myocardial infarction: potentiation of the ischemic process?
2001 Jan
Assessment of autonomic cardiovascular indices in non-stationary data in rats.
2001 Jan
Relaxant effect of Pimpinella anisum on isolated guinea pig tracheal chains and its possible mechanism(s).
2001 Jan
Secretion and gene expression of secretory leukocyte protease inhibitor by human airway submucosal glands.
2001 Jan
Non-synaptic transformation of gustatory receptor potential by stimulation of the parasympathetic fiber of the frog glossopharyngeal nerve.
2001 Jan
Vagosympathetic interactions in ischemia-induced myocardial norepinephrine and acetylcholine release.
2001 Jan
Electrical activation of endothelium evokes vasodilation and hyperpolarization along hamster feed arteries.
2001 Jan
Xerostomia, xerophthalmia, and plasmacytic infiltrates of the salivary glands (Sjögren's-like syndrome) in a cat.
2001 Jan 1
Effects of preemptive atropine administration on incidence of medetomidine-induced bradycardia in dogs.
2001 Jan 1
Post-ictal analgesia: involvement of opioid, serotoninergic and cholinergic mechanisms.
2001 Jan 12
Changes in sensitivity of cholinoceptors and adrenoceptors during transhemispheric cortical reorganisation in rat SmI.
2001 Jan 12
Role of preoptic and anterior hypothalamic cholinergic input on water intake and body temperature.
2001 Jan 19
The effect of nitrate and ammonium concentrations on growth and alkaloid accumulation of Atropa belladonna hairy roots.
2001 Jan 23
Angiotensinergic and noradrenergic mechanisms in the hypothalamic paraventricular nucleus participate in the drinking response induced by activation of the subfornical organ in rats.
2001 Jan 29
Evidence of alpha-adrenoceptor-mediated chronotropic action in children.
2001 Jan-Feb
From 'captive' agonism to insurmountable antagonism: demonstrating the power of analytical pharmacology.
2001 Mar
Role of a central muscarinic cholinergic pathway for relaxation of the proximal urethra during the voiding phase in rats.
2001 Mar
Initiation of distension-induced descending peristaltic reflex in opossum esophagus: role of muscle contractility.
2001 Mar
Muscarinic stimulation increases basal Ca(2+) and inhibits spontaneous Ca(2+) transients in murine colonic myocytes.
2001 Mar
Evidence for a direct action of Tityus serrulatus scorpion venom on the cardiac muscle.
2001 May
The role of nitric oxide on the relaxations of rabbit corpus cavernosum induced by Androctonus australis and Buthotus judaicus scorpion venoms.
2001 May
Patents

Sample Use Guides

Atropine as an antisialagogue or for antivagal effects: initial single dose of 0.5 mg to 1 mg; as an antidote for organophosporous or muscarinic mushroom poisoning: initial single dose of 2 mg to 3 mg, repeated every 20­-30 minutes; for bradyasystolic cardiac arrest: 1 mg dose, repeated every 3-5 minutes if asystole persists; in patients with coronary artery disease: total dose should not exceed 0.03 mg/kg to 0.04 mg/kg.
Route of Administration: Other
In Vitro Use Guide
Atropine in doses -5.44 to -4.74 log mol/L totally inhibited the contraction induced by acetylcholine and carbachol in segmental pulmonary artery specimens taken from the patients undergoing thoracic surgery.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:59:16 GMT 2023
Edited
by admin
on Fri Dec 15 16:59:16 GMT 2023
Record UNII
03J5ZE7KA5
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ATROPINE SULFATE
EP   MART.   ORANGE BOOK   USP   USP-RS   VANDF   WHO-IP  
Common Name English
ATROPINI SULFAS [WHO-IP LATIN]
Common Name English
BENZENEACETIC ACID, .ALPHA.-(HYDROXYMETHYL)-, 8-METHYL-8-AZABICYCLO(3.2.1)OCT-3-YL ESTER, ENDO-(±)-, SULFATE (2:1) (SALT), MONOHYDRATE
Systematic Name English
ATROPINUM SULPHURICUM
HPUS  
Common Name English
ATROPINE SULFATE [WHO-IP]
Common Name English
ATROPINE SULFATE HYDRATE [JAN]
Common Name English
ATROPINE SULFATE COMPONENT OF LOW-QUEL
Common Name English
ATROPINE SULFATE [ORANGE BOOK]
Common Name English
ATROPINE SULFATE COMPONENT OF LONOX
Common Name English
ATROPINE SULPHATE
Common Name English
BENZENEACETIC ACID, .ALPHA.-(HYDROXYMETHYL)-, 8-METHYL-8-AZABICYCLO(3.2.1)OCT-3-YL ESTER, ENDO-(±)-, SULPHATE (2:1) (SALT), MONOHYDRATE
Official Name English
LONOX COMPONENT ATROPINE SULFATE
Common Name English
ATROPINE SULFATE MONOHYDRATE
MI   WHO-DD  
Common Name English
ATROPINE SULFATE COMPONENT OF COLONAID
Common Name English
1.ALPHA.H,5.ALPHA.H-TROPAN-3.ALPHA.-OL (±)-TROPATE (ESTER), SULPHATE (2:1) (SALT) MONOHYDRATE
Systematic Name English
ATROPINE SULFATE COMPONENT OF LOMANATE
Common Name English
ISOPTO ATROPINE
Brand Name English
ATROPINE SULFATE [USP MONOGRAPH]
Common Name English
ATROPINE SULFATE COMPONENT OF LOMOTIL
Common Name English
DI-ATRO COMPONENT ATROPINE SULFATE
Common Name English
LO-TROL COMPONENT ATROPINE SULFATE
Common Name English
ATROPINE SULFATE COMPONENT OF ENLON-PLUS
Common Name English
NSC-755889
Code English
ATROPINE SULFATE COMPONENT OF MOTOFEN
Common Name English
ATROPINE SULFATE HYDRATE
JAN  
Common Name English
MOTOFEN COMPONENT ATROPINE SULFATE
Common Name English
ATROPINE SULFATE COMPONENT OF LO-TROL
Common Name English
BENZENEACETIC ACID, .ALPHA.-(HYDROXYMETHYL)- (3-ENDO)-8-METHYL-8-AZABICYCLO(3.2.1)OCT-3-YL ESTER, SULFATE (2:1) (SALT), MONOHYDRATE
Systematic Name English
SYD-101
Code English
COLONAID COMPONENT ATROPINE SULFATE
Common Name English
ENLON-PLUS COMPONENT ATROPINE SULFATE
Common Name English
ATROPINE SULFATE [USP-RS]
Common Name English
ATROPINE SULFATE [VANDF]
Common Name English
ATROPINE SULFATE COMPONENT OF DI-ATRO
Common Name English
ATROPT
Brand Name English
BENZENEACETIC ACID, .ALPHA.-(HYDROXYMETHYL)- (3-ENDO)-8-METHYL-8-AZABICYCLO(3.2.1)OCT-3-YL ESTER, SULPHATE (2:1) (SALT), MONOHYDRATE
Systematic Name English
(±)-ENDO-8-METHYL-8-AZABICYCLO(3.2.1)OCT-3-YL .ALPHA.-(HYDROXYMETHYL)BENZENEACETATE SULFATE (2:1) (SALT) MONOHYDRATE
Systematic Name English
ATROPISOL
Brand Name English
ATROPINE SULFATE [MART.]
Common Name English
LOMOTIL COMPONENT ATROPINE SULFATE
Common Name English
LOGEN COMPONENT ATROPINE SULFATE
Common Name English
Atropine sulfate monohydrate [WHO-DD]
Common Name English
ATROPINE SULFATE MONOHYDRATE [MI]
Common Name English
ATROPINE SULFATE [EP MONOGRAPH]
Common Name English
ATROPINUM SULPHURICUM [HPUS]
Common Name English
LOW-QUEL COMPONENT ATROPINE SULFATE
Common Name English
1.ALPHA.H,5.ALPHA.H-TROPAN-3.ALPHA.-OL (±)-TROPATE (ESTER), SULFATE (2:1) (SALT) MONOHYDRATE
Systematic Name English
ATROPINE SULFATE COMPONENT OF LOGEN
Common Name English
LOMANATE COMPONENT ATROPINE SULFATE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29704
Created by admin on Fri Dec 15 16:59:16 GMT 2023 , Edited by admin on Fri Dec 15 16:59:16 GMT 2023
CFR 21 CFR 310.533
Created by admin on Fri Dec 15 16:59:16 GMT 2023 , Edited by admin on Fri Dec 15 16:59:16 GMT 2023
Code System Code Type Description
DRUG BANK
DBSALT000281
Created by admin on Fri Dec 15 16:59:16 GMT 2023 , Edited by admin on Fri Dec 15 16:59:16 GMT 2023
PRIMARY
FDA UNII
03J5ZE7KA5
Created by admin on Fri Dec 15 16:59:16 GMT 2023 , Edited by admin on Fri Dec 15 16:59:16 GMT 2023
PRIMARY
SMS_ID
100000143430
Created by admin on Fri Dec 15 16:59:16 GMT 2023 , Edited by admin on Fri Dec 15 16:59:16 GMT 2023
PRIMARY
RS_ITEM_NUM
1045009
Created by admin on Fri Dec 15 16:59:16 GMT 2023 , Edited by admin on Fri Dec 15 16:59:16 GMT 2023
PRIMARY
EPA CompTox
DTXSID3040724
Created by admin on Fri Dec 15 16:59:16 GMT 2023 , Edited by admin on Fri Dec 15 16:59:16 GMT 2023
PRIMARY
NCI_THESAURUS
C2744
Created by admin on Fri Dec 15 16:59:16 GMT 2023 , Edited by admin on Fri Dec 15 16:59:16 GMT 2023
PRIMARY
CAS
5908-99-6
Created by admin on Fri Dec 15 16:59:16 GMT 2023 , Edited by admin on Fri Dec 15 16:59:16 GMT 2023
PRIMARY
EVMPD
SUB00625MIG
Created by admin on Fri Dec 15 16:59:16 GMT 2023 , Edited by admin on Fri Dec 15 16:59:16 GMT 2023
PRIMARY
DAILYMED
03J5ZE7KA5
Created by admin on Fri Dec 15 16:59:16 GMT 2023 , Edited by admin on Fri Dec 15 16:59:16 GMT 2023
PRIMARY
EVMPD
SUB120273
Created by admin on Fri Dec 15 16:59:16 GMT 2023 , Edited by admin on Fri Dec 15 16:59:16 GMT 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
ATROPINE SULFATE
Created by admin on Fri Dec 15 16:59:16 GMT 2023 , Edited by admin on Fri Dec 15 16:59:16 GMT 2023
PRIMARY Description: Colourless crystal or a white, crystalline powder; odourless. Solubility: Soluble in less than 1 part of water; freely soluble in ethanol (~750 g/l) TS; practically insoluble in ether R and benzene R. Category: Cholinergic blocking agent (parasympatholytic). Storage: Atropine sulfate should be kept in a tightly closed container, protected from light. Additional information: Atropine sulfate is very poisonous; it effloresces in dry air; it is slowly affected by light. Definition: Atropine sulfate contains not less than 98.5% and not more than 101.0% of (C17H23NO3)2,H2SO4, calculated with reference to the dried substance.
ChEMBL
CHEMBL517712
Created by admin on Fri Dec 15 16:59:16 GMT 2023 , Edited by admin on Fri Dec 15 16:59:16 GMT 2023
PRIMARY
NSC
755889
Created by admin on Fri Dec 15 16:59:16 GMT 2023 , Edited by admin on Fri Dec 15 16:59:16 GMT 2023
PRIMARY
EVMPD
SUB126811
Created by admin on Fri Dec 15 16:59:16 GMT 2023 , Edited by admin on Fri Dec 15 16:59:16 GMT 2023
ALTERNATIVE
MERCK INDEX
m2136
Created by admin on Fri Dec 15 16:59:16 GMT 2023 , Edited by admin on Fri Dec 15 16:59:16 GMT 2023
PRIMARY Merck Index
RXCUI
153971
Created by admin on Fri Dec 15 16:59:16 GMT 2023 , Edited by admin on Fri Dec 15 16:59:16 GMT 2023
PRIMARY RxNorm
Related Record Type Details
ANHYDROUS->SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY
http://apps.who.int/phint/pdf/b/Jb.6.1.38.pdf